REFERENCES
1. Pikor LA, Ramnarine VR, Lam S, Lam WL. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer 2013;82:179-89.
2. Chia PL, Mitchell P, Dobrovic A, John T. Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors. Clin Epidemiol 2014;6:423-32.
3. Kim H, Chung JH. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. Transl Lung Cancer Res 2015;4:149-55.
4. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018;553:446-54.
5. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32:605-44.
6. Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, et al. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016;11:1653-71.
7. Holla VR, Elamin YY, Bailey AM, Johnson AM, Litzenburger BC, et al. ALK: a tyrosine kinase target for cancer therapy. Cold Spring Harb Mol Case Stud 2017;3:a001115.
8. Webb TR, Slavish J, George RE, Look AT, Xue L, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56.
9. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49.
10. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
11. Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol 2016;27 Suppl 3:iii4-15.
12. Ou SI, Shirai K. Anaplastic lymphoma kinase (ALK) signaling in lung cancer. Adv Exp Med Biol 2016;893:179-87.
13. Iyevleva AG, Raskin GA, Tiurin VI, Sokolenko AP, Mitiushkina NV, et al. Novel ALK fusion partners in lung cancer. Cancer Lett 2015;362:116-21.
14. Sabir SR, Yeoh S, Jackson G, Bayliss R. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel) 2017;9:118.
15. Christopoulos P, Endris V, Bozorgmehr F, Elsayed M, Kirchner M, et al. EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK + non-small cell lung cancer. Int J Cancer 2018;142:2589-98.
16. Shaw AT, Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. Available from: https://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer. [Last accessed on 16 Jan 2019].
17. Wu YC, Chang IC, Wang CL, Chen TD, Chen YT, et al. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS One 2013;8:e70839.
18. Letovanec I, Finn S, Zygoura P, Smyth P, Soltermann A, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European thoracic oncology platform lungscape project. J Thorac Oncol 2018;13:413-25.
19. Hanna N, Johnson D, Temin S, Baker S Jr, Brahmer J, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:3484-515.
20. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2015;33:3488-515.
21. Novello S, Barlesi F, Califano R, Cufer T, Ekman S, et al. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016;27:v1-27.
22. Chen Y, Fu L. Mechanisms of acquired resistance to tyrosine kinase inhibitors. Acta Pharmaceutica Sinica B 2011;1:197-207.
23. Remon J, Besse B. Brain metastases in oncogene-addicted non-small cell lung cancer patients: incidence and treatment. Front Oncol 2018;8:88.
24. Rocco D, Battiloro C, Della Gravara L, Gridelli C. Safety and tolerability of anaplastic lymphoma kinase inhibitors in non-small-cell lung cancer. Drug Saf 2018; doi: 10.1007/s40264-018-0771-y.
25. Kazandjian D, Blumenthal GM, Chen HY, He K, Patel M, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014;19:e5-11.
26. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-77.
27. Solomon BJ, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in alk-mutation-positive non-small-cell lung cancer. J Clin Oncol 2018;36:2251-8.
28. Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet 2017;389:917-29.
29. Camidge RD, Peters S, Mok T, Gadgeel SM, Cheema PK, et al. Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs crizotinib (CZ) in untreated advanced ALK + NSCLC. J Clin Oncol 2018;36:9043.
30. Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 2015;21:2436-9.
31. Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, et al. FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following crizotinib. Clin Cancer Res 2016;22:5171-6.
32. Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol 2017;35:2490-8.
33. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
34. Costa DB. Resistance to ALK inhibitors: pharmacokinetics, mutations or bypass signaling? Cell Cycle 2017;16:19-20.
35. Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B 2015;5:34-7.
36. Rothenstein JM, Chooback N. ALK inhibitors, resistance development, clinical trials. Curr Oncol 2018;25:S59-67.
37. Katayama R. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer. Cancer Sci 2018;109:572-80.
38. Lin JJ, Riely GJ, Shaw AT, et al. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov 2017;7:137-55.
39. Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 2016;6:1118-33.
